摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-氨基-2-甲基-2-丙醇盐酸盐 | 30533-50-7

中文名称
1-氨基-2-甲基-2-丙醇盐酸盐
中文别名
1-氨基-2-丙醇盐酸盐;1-氨基-2-甲基-丙-2-醇盐酸盐
英文名称
2-(aminomethyl)-2-propanol hydrochloride
英文别名
1-amino-2-methyl-propan-2-ol; hydrochloride;1-amino-2-methyl-2-propanol hydrochloride;(2-Hydroxy-2-methylpropyl)azanium;chloride;(2-hydroxy-2-methylpropyl)azanium;chloride
1-氨基-2-甲基-2-丙醇盐酸盐化学式
CAS
30533-50-7
化学式
C4H11NO*ClH
mdl
——
分子量
125.598
InChiKey
HZPAJUSRVJDTMT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.14
  • 重原子数:
    7
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    46.2
  • 氢给体数:
    3
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2922199090

SDS

SDS:5e6fbb79af1d03c5e5dde4706c86b2b2
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Amino-2-methylpropan-2-ol, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Amino-2-methylpropan-2-ol, HCl
CAS number: 30533-50-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H12ClNO
Molecular weight: 125.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSÉS UTILES POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS
    申请人:SATORI PHARMACEUTICALS INC
    公开号:WO2011109657A1
    公开(公告)日:2011-09-09
    As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.
    如本文所述,本发明提供了用于治疗或减轻神经退行性疾病严重程度的化合物。本发明还提供了治疗或减轻此类疾病严重程度的方法,其中所述方法包括向患者施用本发明的化合物或其组合物。该方法适用于治疗或减轻例如阿尔茨海默病等疾病的严重程度。
  • [EN] 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER<br/>[FR] 2-HÉTÉROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES POUR LE TRAITEMENT DU CANCER
    申请人:BAYER AG
    公开号:WO2018146010A1
    公开(公告)日:2018-08-16
    The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I), in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    本发明涵盖了一般式(I)的2-杂环芳基-3-酮基-2,3-二氢吡啶嗪-4-羧酰胺化合物,其中X、R1、R2、R3、R4和R5如本文所定义,制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是癌症或与异常AHR信号传导相关的疾病,或与失调免疫反应或其他与异常AHR信号传导相关的疾病,作为单一药剂或与其他活性成分组合使用。
  • [EN] SUBSTITUTED N-ALKYLPYRIMIDINONES<br/>[FR] N-ALKYLPYRIMIDINONES SUBSTITUES
    申请人:PHARMACIA & UPJOHN CO LLC
    公开号:WO2006040666A1
    公开(公告)日:2006-04-20
    This invention is directed generally to substituted pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such substituted pyrimidinone include compounds generally corresponding in structure to the following formula (I): wherein R1, R2, R3, R4A, R4B, R4C, R4D and R4E are as defined in this specification. This invention also is directed to compositions of such substituted pyrimidinones (particularly pharmaceutical compositions), intermediates for the syntheses of such substituted pyrimidinones, methods for making such substituted pyrimidinones, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.
    本发明一般涉及取代吡啶酮化合物,这些化合物通常抑制p38激酶、肿瘤坏死因子(TNF)和/或环氧合酶活性。这类取代吡啶酮包括与以下公式(I)结构相对应的化合物:其中R1、R2、R3、R4A、R4B、R4C、R4D和R4E按本说明书定义。本发明还涉及这些取代吡啶酮的组成物(特别是药物组成物)、用于合成这些取代吡啶酮的中间体、制造这些取代吡啶酮的方法,以及用于治疗(包括预防)与p38激酶活性、TNF活性和/或环氧合酶-2活性相关的病症(通常是病理状况)的方法。
  • [EN] SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER<br/>[FR] BENZOTHIÉNYL - PYRROLOTRIAZINES SUBSTITUÉES ET UTILISATIONS DE CELLES-CI POUR LE TRAITEMENT DU CANCER
    申请人:BAYER IP GMBH
    公开号:WO2013087647A1
    公开(公告)日:2013-06-20
    This invention relates to novel substituted 5-(l-benzothiophen-2-yl)pyrrolo[2,l-fJ[l,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.
    这项发明涉及新型的取代5-(1-苯并噻吩-2-基)吡咯并[2,1-f][1,2,4]三嗪-4-胺衍生物,具有蛋白酪氨酸激酶抑制活性,以及制备这类化合物的方法,含有这类化合物的药物组合物,以及利用这类化合物或组合物治疗增殖性疾病,特别是癌症和肿瘤疾病。
  • [EN] PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS<br/>[FR] COMPOSÉS DE PYRIMIDINE ET LEUR UTILISATION COMME MODULATEURS DE LA GAMMA-SÉCRÉTASE
    申请人:ACTURUM LIFE SCIENCE AB
    公开号:WO2014195323A1
    公开(公告)日:2014-12-11
    The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of Aβ-related diseases.
    本发明涉及式(I)化合物及其药用可接受的盐。该发明还涉及包含这些化合物的药物组合物,制造这些化合物的方法,以及它们作为治疗和/或预防Aβ相关疾病的药物的应用。
查看更多